Amplifon consensus steady ahead of July earnings, shares on the OTC market

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 14:11.

Amplifon (IT0004056880) enters late June with a clear analyst view on its stock. The Milan-based hearing-care retailer’s shares trade in the US on the OTC market, and the next estimated earnings date sits at 2026-07-30 according to MarketBeat data.

What the consensus shows today

MarketBeat lists Amplifon in the medical services sector, with a trailing twelve-month earnings per share of 0.36 dollars and a trailing P/E ratio of roughly 31.1 as of June 24, 2026. The platform’s overview places the stock in its medical category with an estimated next earnings date at the end of July 2026.

The same data set indicates a forward P/E ratio reported around 2.95, suggesting analyst models expect earnings growth in the coming periods relative to the current share price. For retail investors, that gap between trailing and forward multiples is a key metric when comparing Amplifon to other healthcare and consumer names such as Sonova or GN Store Nord.

Analyst attention on margins and growth

Amplifon’s last reported earnings date on MarketBeat is June 1, 2026, marking the most recent quarterly checkpoint for margins and store expansion. With the next update estimated for July 30, 2026, brokers and portfolio managers focus on how the company balances organic growth, acquisitions and operating leverage across its global retail footprint.

In sector context, Amplifon competes with hearing-care players including Sonova and Demant, which also pursue international networks of audiology centers and branded devices. Research coverage from houses such as UBS and Deutsche Bank on the broader hearing-aid segment has highlighted the importance of stable reimbursement frameworks and aging demographics in Europe and North America, factors that also underpin the investment case for Amplifon according to recent broker commentary from the space.

How Amplifon makes its money

Amplifon’s core business is hearing care retail. The company operates thousands of stores and service points worldwide, selling and fitting hearing aids and related accessories for customers, often under the Amplifon brand and through partnerships with device manufacturers, as outlined on its corporate site. Revenue is driven by product sales and ongoing services such as fitting, adjustments and follow-up consultations in its clinics.

Where the shares trade today

Amplifon shares (IT0004056880) are listed primarily on the Borsa Italiana in Milan, with an additional OTC listing under the ticker AMFPF in the US market according to MarketBeat’s stock overview. As of 2026-06-24, the OTC quotation stands at 11.21 dollars per share on the AMFPF line.

This article provides non-binding, journalistic information on the Amplifon shares and does not constitute investment advice or a recommendation to buy or sell securities.